Cargando…

Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review

BACKGROUND: Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. OBJECTIVES: To evaluate the efficacy and safety of rituximab for MS treatment. DATA COLLECTION: Studies were selected if they were cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castillo-Trivino, Tamara, Braithwaite, Dejana, Bacchetti, Peter, Waubant, Emmanuelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699597/ https://www.ncbi.nlm.nih.gov/pubmed/23843952 http://dx.doi.org/10.1371/journal.pone.0066308

Ejemplares similares

Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery
por: Mowry, Ellen M., et al.
Publicado: (2013)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis
por: Waubant, Emmanuelle
Publicado: (2006)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
por: Castillo-Trivino, Tamara, et al.
Publicado: (2011)

Biosensor vital sign detects multiple sclerosis progression
por: Krysko, Kristen M., et al.
Publicado: (2020)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis
por: Bischof, Antje, et al.
Publicado: (2022)

Association of Multiple Sclerosis Susceptibility Variants and Early Attack Location in the CNS
por: Mowry, Ellen M., et al.
Publicado: (2013)

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
por: Dorcet, Guillaume, et al.
Publicado: (2022)

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”
Publicado: (2021)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

Is multiple sclerosis a risk factor for infections?
por: Lechner-Scott, Jeannette, et al.
Publicado: (2020)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2023)

Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis
por: Salehizadeh, Saeideh, et al.
Publicado: (2022)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

High-dose vitamin D(3) supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial
por: Cassard, Sandra D., et al.
Publicado: (2023)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

SncRNA (microRNA & snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent
por: Muñoz-Culla, Maider, et al.
Publicado: (2016)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

The role of gut microbiota in shaping the relapse-remitting and chronic-progressive forms of multiple sclerosis in mouse models
por: Gandy, K. Alexa Orr, et al.
Publicado: (2019)

Systematic review of prediction models in relapsing remitting multiple sclerosis
por: Brown, Fraser S., et al.
Publicado: (2020)

No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)
por: Bonnan, Mickael, et al.
Publicado: (2021)

Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course
por: Nourbakhsh, Bardia, et al.
Publicado: (2018)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Transcriptomic Profile Reveals Gender-Specific Molecular Mechanisms Driving Multiple Sclerosis Progression
por: Irizar, Haritz, et al.
Publicado: (2014)

Silent progression in disease activity–free relapsing multiple sclerosis
por: Cree, Bruce A. C., et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Patterns of attention deficit in relapsing and progressive phenotypes of multiple sclerosis
por: Tabibian, Farinaz, et al.
Publicado: (2023)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02kfp0jgd8o0kaj8tv9sngnnd2